Get your money out of INO and into NK
Soon-Shiong is for real and has a tech that attracts T-Cells to the target....natural killer cells.
Pipeline is HUGE. Celgene already in big
aNK = "activated" Natural Killer ...unique "off the shelf-in a bag" cell line
......that isn't de-activated by the cancer cells ability to hide
Into Phase II: Merkel cell carcinoma
Phase I/II trials done:
haNK =high affinity Natural Killer... NK cells customized to enhance antibody therapies
Phase I complete
Metastatic Breast (Herceptin - haNK)
Metastatic Breast (Perjeta - hank)
Gastroesophageal (Herceptin - haNK)
Non-Hodgkin's Lymphoma (Rituxan - haNK)
Hodgkin's Lymphoma (Rituxan - haNK)
Chronic Lymphocytic Leukemia CLL (Gazyva - haNK)
Ewing's Sarcoma (Ganitumab -haNK)
Metastatic Pancreatic (Ganitumab -haNK)
taNK = targeted Natural Killer ..engineered with Car-T technology for
scalability, quality control and consistency
taNK ... complete Phase I
Renal Cell Carcinoma
Mantle Cell Lymphoma
AML Acute Myeloid Leukemia
AML Acute Myeloid Leukemia
taNK = targeted Natural Killer ..Pre IND (preclinical)
After some "natural killer" cells trials success, I see them collaborating with every Car-T cell company for use in combination with every successful one....with patients looking to avoid damaging Chemo-therapies Those PRs will appear endless...and originated from the other companies
NK patients have seen total remissions in non-Hodgkins lymphoma and NK's Ph-I a trial has revealed safety and non-toxicity.
This thing will roll big considering the multiple indications of cancer and all manner of pathologies.
This may be on the verge of the biggest Biomedical platforms ever.
That is why billionaire Soon-Shiong is risking big money here.
NK’s targeted therapeutic areas include:
(1) cancer, focusing on bulky hematological cancers and solid tumors as well as cancer stem cells,
(2) infectious diseases, including viral, fungal and bacterial infections, and
(3) inflammatory diseases, ranging from rare inherited diseases to more prevalent autoimmune disorders.
Sham awards---lots of those! . No profits. Maybe some grants...like a 35 yo incubator startup pre- clinical penny stock.
But I suppose ceramics such as Oxinium and super polyethylenes will have to wait until they are merged with another company with far more applications
Fitbit IPO was June 17, 2015. I found options trading by June 30, 2015.....two weeks later ....and not just six months out...there are LEAPS out to Jan 2017
You sound a llitle desperate, AMBA shorty. One more day of 12 million shares covered of the 24 million that were shorted Monday and we will be up another $10-$15
You have heard of AMBA right?
VDSI will gain in share price accordingly.
Really? Hardly....Get real. This is hot sector and will never go away....like national defense.
according to yahoo. VDSI has yoy growth 68% G margin 61% op margins 22% and pe less than 30
Market Cap: 1.29B
Qtrly Rev Growth (yoy): 0.68
Revenue (ttm): 227.85M
Gross Margin (ttm): 0.61
EBITDA (ttm): 50.34M
Operating Margin (ttm): 0.22
Net Income (ttm): 42.74M
EPS (ttm): 1.10
P/E (ttm): 29.58